Loading stock data…
TXG
$30.59+1.41 (+4.83%)
Market ClosedLast close Jun 9
10x Genomics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
10x Genomics, Inc. in the Healthcare sector is trading at $30.59 with a market capitalization of $4.1B. Wall Street consensus targets $25.77 (13 analysts), implying a -15.8% move over the next 12 months. The stock is currently near its 52-week high of $35.65, remaining 65.4% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply -15.8% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$30.59
Potential Downside
0%
Whystock Fair Value$30.59
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Buy
Mean target$25.77-15.8%
Range$20.00 – $32.00
Fundamentals
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.78%
Volume
Today's trading volume
3.19M
Recent News
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.
10x Genomics, a leader in single cell and spatial genomics tools, reported a notable insider sale amid ongoing sector innovation.
The 5 Most Interesting Analyst Questions From 10x Genomics’s Q1 Earnings Call
10x Genomics' first quarter results were met with a negative market reaction, despite exceeding Wall Street’s revenue and earnings expectations. Management credited continued momentum in single cell and spatial consumable volumes, particularly from newer product lines like FLEX Apex and Xenium. CEO Serge Saxonov emphasized that the recent Atara launch was a pivotal development, describing it as a response to longstanding customer demands for scalable, high-resolution spatial biology tools. The c
1 Cash-Producing Stock on Our Watchlist and 2 We Question
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Is It Time To Reassess 10x Genomics (TXG) After Its Recent Share Price Surge?
If you are trying to work out whether 10x Genomics at around US$20.92 is still good value or already pricing in a lot of optimism, it helps to break the story into simple numbers first. The stock has fallen about 5.0% over the last week and 10.1% over the last month, yet it is still up 25.9% year to date and 116.8% over the past year. However, longer term 3 year and 5 year returns are down 59.9% and 86.1% respectively, which makes timing and valuation especially important. Recent coverage...
Why 10x Genomics (TXG) Stock Is Down Today
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.3% in the afternoon session after its first-quarter results, although beating expectations, were overshadowed by concerns about its future growth prospects.